EUVIMEDEUVIMED entdecken
Crossref

Tick‐Borne Encephalitis Virus Surveillance—Vaccination‐ and Infection‐Induced Seroprevalences in Western Austria 2024

Anita Siller iD, Lidia Chitimia-Dobler, Wolfgang Hitzl, Manfred Astl, Harald Schennach, Peter Fraunberger, Janne Cadamuro, Johannes P Borde iD, Peter Willeit iD, Gerhard Dobler, Sylvia Mink iD

Journal of Medical Virology · 2024

DOI: 10.1002/jmv.70109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Anita Siller und 10 weiteren Autor:innen. Beteiligte Einrichtung: Central Institute for Blood Transfusion and Immunology, University Hospital of Innsbruck, Tirol Kliniken GmbH, Innsbruck, Austria. Hauptthemen laut MEDLINE: Encephalitis, Tick-Borne, Encephalitis Viruses, Tick-Borne, Antibodies, Viral, Immunoglobulin G. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: This study was funded as an investigator driven study by Pfizer Pharma GmbH grant (general research grant no. 67542165)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reported tick‐borne‐encephalitis (TBE) cases have been increasing in Western Austria, but no data are available on vaccination‐ and infection‐specific seroprevalence. This study aimed to estimate current TBEV‐seroprevalence in the region and inform prevention programs by comparing anti‐NS1‐based‐incidence rates with reported case numbers and vaccination coverage. Between December 2023 and February 2024, serum samples from 4619 blood donors in Western Austria were collected and analyzed using TBEV‐ and WNV‐IgG‐ELISA assays. Seropositive samples were tested with a TBEV‐anti‐NS1‐IgG‐ELISA to distinguish infections from vaccinations. Borderline samples were retested with serum neutralization and triple‐NS1‐assays. The overall anti‐TBEV‐IgG‐seroprevalence was 80.1% (95%CI 78.9–81.3); 2.7% (95%CI 2.3–3.2) of donors tested positive for anti‐TBEV‐NS1 IgG antibodies, indicating previous infection. The notified incidence rate in Western Austria was 2.7/100 000/year, compared to 136.2/100 000/year based on anti‐TBEV‐NS1‐seropositive donors, denoting a substantial number of unreported cases (mean manifestation index 1.9%). The number of donors with TBEV‐infections varied considerably by district, highlighting potential hotspots for TBEV‐infections. The high anti‐NS1‐based, estimated annual TBE incidence rates show significant differences between districts, highlighting the need for targeted prevention programs. The high rate of undiagnosed TBE cases further suggests that estimated anti‐NS1‐based incidence rates should be considered when defining high‐risk areas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Encephalitis, Tick-BorneEncephalitis Viruses, Tick-BorneAntibodies, ViralImmunoglobulin GHumansAustriaSeroepidemiologic StudiesFemaleMaleMiddle AgedAdultIncidenceYoung AdultVaccinationEnzyme-Linked Immunosorbent AssayAgedAdolescentBlood DonorsViral Vaccines

Stichwörter der Autor:innen

IgG antibody surveillanceincidenceseroprevalencetick‐borne encephalitis

Substanzen

Antibodies, ViralImmunoglobulin GViral Vaccines

Autor:innen und Institutionen

  • Central Institute for Blood Transfusion and Immunology, University Hospital of Innsbruck, Tirol Kliniken GmbH, Innsbruck, Austria.
  • Bundeswehr Institute for Microbiology, National TBEV Consultant Laboratory, Munich, Germany.
  • Fraunhofer-Institute for Immunology, Infection and Pandemic Research, Penzberg, Germany.
  • Department of Research and Innovation, Team Biostatistics and Publication of Clinical Trials, Paracelsus Medical University, Salzburg, Austria.
  • Central Medical Laboratories, Feldkirch, Austria.
  • Private University in the Principality of Liechtenstein, Triesen, Liechtenstein.

ORCID-Profile: Anita Siller, Johannes P Borde, Peter Willeit, Sylvia Mink

Förderung

  • This study was funded as an investigator driven study by Pfizer Pharma GmbH grant (general research grant no. 67542165).

Zitieren

APA

Siller, A., Chitimia-Dobler, L., Hitzl, W., Astl, M., Schennach, H., Fraunberger, P., Cadamuro, J., Borde, J. P., Willeit, P., Dobler, G., & Mink, S. (2024). Tick‐Borne Encephalitis Virus Surveillance—Vaccination‐ and Infection‐Induced Seroprevalences in Western Austria 2024. Journal of Medical Virology. https://doi.org/10.1002/jmv.70109

Vancouver

Siller A, Chitimia-Dobler L, Hitzl W, Astl M, Schennach H, Fraunberger P, et al. Tick‐Borne Encephalitis Virus Surveillance—Vaccination‐ and Infection‐Induced Seroprevalences in Western Austria 2024. Journal of Medical Virology. 2024. doi:10.1002/jmv.70109

BibTeX
@article{Siller2024,
  author = {Siller, Anita and Chitimia-Dobler, Lidia and Hitzl, Wolfgang and Astl, Manfred and Schennach, Harald and Fraunberger, Peter and Cadamuro, Janne and Borde, Johannes P and Willeit, Peter and Dobler, Gerhard and Mink, Sylvia},
  title = {Tick‐Borne Encephalitis Virus Surveillance—Vaccination‐ and Infection‐Induced Seroprevalences in Western Austria 2024},
  journal = {Journal of Medical Virology},
  year = {2024},
  doi = {10.1002/jmv.70109}
}
Kostenlos starten →